E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of infection with the coronavirus |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051905 |
E.1.2 | Term | Coronavirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10084510 |
E.1.2 | Term | Coronavirus infections |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084529 |
E.1.2 | Term | 2019 novel coronavirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this clinical trial is to learn about the safety, tolerability and immune response of BNT162b RNA-based SARS-CoV-2 vaccine candidates to prevent COVID-19 in participants aged 12 years and older. |
|
E.2.2 | Secondary objectives of the trial |
The secondary purpose of this clinical trial is to learn about the immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates to prevent COVID-19 in participants aged 12 years and older. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age: Cohort 1: 18 through 55 years of age; Cohort 2: 12 years of age and older; Cohort 3: 18 years of age and older; Cohort 4: 18 through 55 years of age. 2. Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations. 3. Healthy participants (stable pre-existing disease permitted). 4. Capable of giving signed informed consent. 5. Prior COVID-19 vaccination history: 6. Cohort 1 only: Received of 1 booster dose of a US-authorized COVID-19 vaccine, with the dose being 90 or more days before first study visit. Documented receipt of all prior COVID-19 vaccines is required. 7. Cohorts 2 and 3 only: Received 3 prior doses of 30 micrograms BNT162b2, with last dose being 150 to 365 days before first study visit. Documented receipt of all prior COVID-19 vaccines is required. 8. Cohort 4 only: Received 3 or 4 prior doses of a US-authorized mRNA COVID-19 vaccine (and dose level), with the last dose being a US-authorized Omicron BA.4/BA.5-adapted vaccine and dose level at least 150 days before first study visit. Documented receipt of all prior COVID-19 vaccines is required. |
|
E.4 | Principal exclusion criteria |
1. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines. 2. Known or suspected immunodeficiency. 3. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. 4. Women who are pregnant or breastfeeding. 5. Other medical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 6. Immunosuppressants/radiotherapy: Cohorts 1 and 2 - Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before study vaccination through end of study. Cohorts 3 and 4 - Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study. 7. Blood/plasma products, immunoglobulin, or monoclonal antibodies: Cohorts 1, 2, 3 - Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study vaccination or planned receipt throughout the study. Cohort 4 - Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for treatment/prevention of COVID-19 or those considered immunosuppressive, from 60 days before study vaccination or planned receipt throughout the study. 8. Other study participation: Cohorts 1 and 2 - Participation in other studies involving a study intervention within 28 days before randomization. Anticipated participation in other studies within 28 days after receipt of study intervention in this study. Cohorts 3 and 4 - Participation in other studies involving receipt of a study intervention within 28 days before randomization. Anticipated participation in other studies involving a study intervention from randomization through the end of this study. 9. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members. 10. Cohort 4 only: History of myocarditis or pericarditis |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary safety - Local reactions (pain at the injection site, redness, and swelling) - Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) - AEs - SAEs
Primary Immunogenicity - SARS-CoV-2 Omicron (BA.4/BA.5)– neutralizing titers |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary safety Local and systemic reactions for 7 days following the study vaccination AEs for 1 month following the study vaccination SAEs for 6 months following the study vaccination
Primary Immunogenicity From before study vaccination (Day 1) to 1 month after study vaccination |
|
E.5.2 | Secondary end point(s) |
Secondary Immunogenicity SARS-CoV-2 Omicron (BA.4/BA.5)– neutralizing titers |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From before study vaccination (Day 1) to 1 month after study vaccination. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Cohort 1 & 2 (12-17yrs): Observer-blind, Cohort 2 (18+yrs) & 3: Open-label, Cohort 4: Observer-blind |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 14 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of the last visit of the last participant in the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 1 |